News articles about Pacira Pharmaceuticals (NASDAQ:PCRX) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.5927885378473 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Pacira Pharmaceuticals Inc (PCRX) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Pacira Pharmaceuticals to Present at the 2018 Barclays Global Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Pacira Pharmaceuticals (PCRX) and Juniper Pharmaceuticals (JNP) Critical Contrast (americanbankingnews.com)
- Pacira Pharmaceuticals (PCRX) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Pacira Pharmaceuticals Inc (PCRX) is Tamarack Advisers LP’s 3rd Largest Position (americanbankingnews.com)
Pacira Pharmaceuticals (PCRX) opened at $31.90 on Friday. The stock has a market capitalization of $1,290.56, a PE ratio of -29.27 and a beta of 1.95. Pacira Pharmaceuticals has a fifty-two week low of $29.35 and a fifty-two week high of $52.47. The company has a current ratio of 6.96, a quick ratio of 6.24 and a debt-to-equity ratio of 0.99.
PCRX has been the topic of a number of research analyst reports. Janney Montgomery Scott set a $27.00 price target on Pacira Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, November 16th. Wedbush reissued a “buy” rating and set a $80.00 price target on shares of Pacira Pharmaceuticals in a report on Monday, November 20th. Mizuho lowered Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $53.00 to $44.00 in a report on Wednesday, November 29th. Canaccord Genuity set a $42.00 price target on Pacira Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. initiated coverage on Pacira Pharmaceuticals in a report on Monday, December 18th. They set a “neutral” rating and a $47.00 price target on the stock. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $45.29.
In related news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.60% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3253546/pacira-pharmaceuticals-pcrx-earns-news-sentiment-score-of-0-13.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.